Zentek's Triera Biosciences to offer CRO services

Executive Summary

• Zentek Ltd.'s wholly owned subsidiary, Triera Biosciences Ltd., is launching Contract Research Organization (CRO) services focused on custom aptamer discovery, biosensor enablement, and machine learning classification support.
• The service targets pharmaceutical, biotechnology, and diagnostics organizations in North America, Europe, and other markets lacking in-house SELEX expertise or biosensor engineering capabilities.
• Triera operates on an asset-light, client-financed model where the company retains ownership of all underlying intellectual property, aiming to generate near-term revenue to support internal development and long-term product roadmaps.

Key Details

• Service Offerings: The CRO services integrate three core capabilities: (i) custom aptamer discovery and optimization via SELEX; (ii) biosensor engineering and integration support; and (iii) optional machine learning (ML) classification systems for signal interpretation.
• Scientific Foundation: Triera’s platform is built on a collaboration with Dr. Yingfu Li’s research team at McMaster University.
• Licensing Terms: Triera holds an exclusive, worldwide, royalty-bearing license from McMaster University to use and practice aptamer applications for the next 20 years.
• Technical Capabilities: Aptamers are chemically synthesized, allowing for consistent batch-to-batch production, rapid iteration, and defined stability profiles. Selected research targets have reported binding affinity values (Kd) in the subnanomolar range.
• Current Portfolio: The current catalogue includes aptamers for clinically significant targets such as influenza A, SARS-CoV-2, vascular endothelial growth factor (VEGF), syphilis, norovirus, and Clostridioides difficile.
• Business Model: Triera acts as an upstream molecular recognition supplier, delivering validated aptamer sequences and biosensor-ready outputs while retaining IP ownership. Client engagements are financed by the client.
• Strategic Rationale: The launch aligns with Zentek’s strategy to generate earlier and more predictable revenue, supporting internal development capacity and broader diagnostic/pharmaceutical initiatives. Successful engagements may lead to follow-on programs, licensing, or product partnerships.

Notable Quotes

• "Triera was built to commercialize a deep body of aptamer science into real-world diagnostics and therapeutics... By offering CRO services, we can help pharmaceutical and biotech teams access custom molecular recognition tools and accelerate their development timelines, while generating near-term revenue that supports Triera's long-term product road map." — Mohammed (Moe) Jiwan, CEO of Zentek